» Articles » PMID: 19738203

Oncogenic EGFR Signaling Networks in Glioma

Overview
Journal Sci Signal
Date 2009 Sep 10
PMID 19738203
Citations 203
Authors
Affiliations
Soon will be listed here.
Abstract

The epidermal growth factor receptor (EGFR) is a primary contributor to glioblastoma (GBM) initiation and progression. Here, we examine how EGFR and key downstream signaling networks contribute to the hallmark characteristics of GBM such as rapid cancer cell proliferation and diffused invasion. Additionally, we discuss current therapeutic options for GBM patients and elaborate on the mechanisms through which EGFR promotes chemoresistance. We conclude by offering a perspective on how the potential of integrative systems biology may be harnessed to develop safe and effective treatment strategies for this disease.

Citing Articles

Multimodal scanning of genetic variants with base and prime editing.

Belli O, Karava K, Farouni R, Platt R Nat Biotechnol. 2024; .

PMID: 39533106 DOI: 10.1038/s41587-024-02439-1.


Andrographolide sensitizes glioma to temozolomide by inhibiting DKK1 expression.

Zhang Z, Gao Z, He J, Ma C, Tao H, Zhu F Br J Cancer. 2024; 131(8):1387-1398.

PMID: 39266624 PMC: 11473956. DOI: 10.1038/s41416-024-02842-0.


Interleukin 4 and cancer resistance in glioblastoma multiforme.

Detchou D, Barrie U Neurosurg Rev. 2024; 47(1):448.

PMID: 39164434 DOI: 10.1007/s10143-024-02695-4.


Structural insights into the role and targeting of EGFRvIII.

Bagchi A, Stayrook S, Xenaki K, Starbird C, Doulkeridou S, El Khoulati R Structure. 2024; 32(9):1367-1380.e6.

PMID: 38908376 PMC: 11380598. DOI: 10.1016/j.str.2024.05.018.


Advances in synthetic lethality modalities for glioblastoma multiforme.

Richard S Open Med (Wars). 2024; 19(1):20240981.

PMID: 38868315 PMC: 11167713. DOI: 10.1515/med-2024-0981.